EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) significantly prolong progression-free survival (PFS) in patients with advanced EGFR mutation-positive (EGFRm) NSCLC compared to chemotherapy as first-line therapy (9–11).